TriangleNCT00005636 · CITED IN SOURCE DOCUMENTS
Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2013-06-19
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: Histologically confirmed malignant mesothelioma of the pleura not amenable to curative surgery Must be radiologically accessible Unidimensionally or bidimensionally measurable disease Pleural effusions or positive bone scan not considered measurable No brain metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 9 g/dL Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase, AST, and ALT no greater than 3.0 times ULN (no greater than 5 times ULN with liver involvement) Albumin at least 3.0 g/dL Renal: Creatinine clearance at least 45 mL/min Other: No serious systemic disorders that may preclude study No prior primary malignancy within the past 5 years except carcinoma in situ of the cervix or adequately treated basal cell carcinoma of the skin No obvious malnourishment or greater than 10% weight loss within 6 weeks prior to study No active infection Not pregnant or nursing Fertile patients must use effective contraception during and for 3 months after study PRIOR CONCURRENT THERAPY: Biologic therapy: Prior immunomodulators allowed for pleurodesis No concurrent immunotherapy Chemotherapy: No prior systemic chemotherapy At least 1 week since prior bleomycin for pleurodesis Prior intracavitary cytotoxic drugs allowed for pleurodesis No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal anticancer therapy Radiotherapy: At least 4 weeks since prior radiotherapy to target lesion Lesion must be clearly progressive No concurrent radiotherapy Surgery: See Disease Characteristics No concurrent surgery for cancer Other: At least 4 weeks since any other prior investigational agent No concurrent aspirin or other nonsteroidal antiinflammatory drug from 2 days prior to 2 days after study (5 days prior for long acting agents such as piroxicam, naproxen, diflunisal, or nabumetone) No other concurrent experimental medications
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- name
- cisplatin
- type
- DRUG
- name
- pemetrexed disodium
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- primary Purpose
- TREATMENT
Enrollment
Source nullRegistered outcome plans (not posted results)
Full study description
- brief Summary
- RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if cisplatin is more effective with or without pemetrexed disodium for malignant mesothelioma of the pleura. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin with or without pemetrexed disodium in treating patients who have malignant mesothelioma of the pleura that cannot be removed by surgery.
- detailed Description
- OBJECTIVES: I. Compare survival in patients with malignant pleural mesothelioma when treated with cisplatin with or without LY231514. II. Compare duration of response, time to progression, and time to treatment failure in these patients with these treatment regimens. III. Compare tumor response rate and clinical benefit of these treatment regimens in these patients. IV. Compare Lung Cancer Symptom Scale scores, pulmonary function test scores, and lung density determinations with these treatment regimens in these patients. V. Compare toxicity of these treatment regimens in these patients. VI. Assess pharmacokinetics and vitamin metabolite status with these treatment regimens in these patients. OUTLINE: This is a randomized, single blind, multicenter study. Patients are stratified according to performance status (Karnofsky 70-80% vs 90-100%), degree of measurability (bidimensional vs unidimensional only), histologic subtype (epithelial vs all others), WBC (8,300/mm3 and higher vs less than 8,300/mm3), pain intensity (low vs high), analgesic consumption (low vs high), dyspnea (low vs high), homocysteine (low vs high), gender, country, and treatment center. Patients are randomized to one of two treatment arms. Arm I: Patients receive LY231514 IV over 10 minutes followed by cisplatin IV over 2 hours on day 1. Arm II: Patients receive cisplatin as in arm I. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks, and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this study within 15 months.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-1f9201dc8c2a43bea982
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 49baf2a0-c1bf-49a8-a2f9-176cae0b7410
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- 5db63bce44ab76c1efd7276a97211400a9f8be2d79994bf6918bf97ded6242a8
- payload
- application numbers
- NDA209472
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-1f9201dc8c2a43bea982
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- s) (95% CI) 6.2 (4.9,8.0) 7.4 (5.6,9.5) Hazard ratio (HR) a (95% CI) 1.32 (0.93,1.86) 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 19167
- exact text
- NCT00005636
- start
- 19156
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/91/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 49baf2a0-c1bf-49a8-a2f9-176cae0b7410
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fabb7322fa01234eab10e933fa6a8ff46ccdac2d8c21ba522dd36a9932c59267
- spl effective time
- 20260618
- spl set id
- caef07ce-066b-4c48-98dc-974b05ebbbe0
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-249b0c4496994d0f3e71
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 6e125601-ebbb-4fe6-9d9e-80d093b12532
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 131a02ebb24aa6929fe585f588fe0ab9667ffe415a47b8a89b661597ebd6693a
- payload
- application numbers
- NDA210661
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-249b0c4496994d0f3e71
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- ) Median (months) (95% CI) 6.2 (4.9-8.0) 7.4 (5.6-9.5) HR a (95% CI) 1.32 (0.93-1.86) 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 18373
- exact text
- NCT00005636
- start
- 18362
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/41/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 6e125601-ebbb-4fe6-9d9e-80d093b12532
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c1815b42252f266daaa6ea7cd4300975a080640af963f58025c7b9cdbdd2075f
- spl effective time
- 20251008
- spl set id
- 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-53f108f6064bf02b103d
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 0c1baa15-83bb-45a0-a3ab-855a4fee9129
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- a0704b01c346250a73f6d1efa5f05768ea64dfb2fa19252cc6a58d568334814e
- payload
- application numbers
- NDA210661
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-53f108f6064bf02b103d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- ) Median (months) (95% CI) 6.2 (4.9-8.0) 7.4 (5.6-9.5) HR a (95% CI) 1.32 (0.93-1.86) 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 13866
- exact text
- NCT00005636
- start
- 13855
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/35/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 0c1baa15-83bb-45a0-a3ab-855a4fee9129
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3795d0040e7ac5a79c69b3e5faa265627002f44394b0c17baa15e8f36a5f9b35
- spl effective time
- 20250205
- spl set id
- adc9ce4c-926a-4ee8-bd0d-d06fc89c17fc
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-5f6f005926e6d0936d38
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 3af0bc84-13d6-46aa-a4c0-c62410b73bc6
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- c4c4d79708a940b3b99ee734cff07bb7ccf982528da7f9ae6ad0fe801d709721
- payload
- application numbers
- NDA021462
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-5f6f005926e6d0936d38
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- =172) Median (months) (95% CI) 6.2 (4.9-8.0) 7.4 (5.6-9.5) HR a (95% CI) 1.32 (0.93-1.86) 14.2 Mesothelioma The efficacy of ALIMTA was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 18681
- exact text
- NCT00005636
- start
- 18670
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/21/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 3af0bc84-13d6-46aa-a4c0-c62410b73bc6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c363caf02e37fe1fcb2cfbfab2db667a44fdc5d833da1aa84c45ac81f6d9476f
- spl effective time
- 20230519
- spl set id
- f5a860f3-37ec-429c-ae04-9c88d7c55c08
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-6168c475f12efb9f4e60
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- b6a00be1-95d1-4b91-93bf-4430a57eeff6
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- cddf735a28c78222c4a750219b637e7589fdd971f84312c0acb2a8b6d684651a
- payload
- application numbers
- NDA215179
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-6168c475f12efb9f4e60
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- as adenocarcinoma, large cell carcinoma, or squamous cell carcinoma. 1 1 1 1 1 1 1 1 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 18846
- exact text
- NCT00005636
- start
- 18835
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/19/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b6a00be1-95d1-4b91-93bf-4430a57eeff6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3e0c2b31c3caff21c791ca789dbbe8d786d7c6e66e0c8ecae4db8285b6897301
- spl effective time
- 20250708
- spl set id
- 0f006b06-ab85-423d-ba0c-dfc3fc25844e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-936159c7f8fb3c691c64
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 54cf7e63-ef81-4ced-b833-a73ad8980230
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 9a8cf26993a5e26667dce63aa78b214f2c824928a3dbfcf3ab5b29d7800db71f
- payload
- application numbers
- NDA214218
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-936159c7f8fb3c691c64
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- 72) Median (months) 6.2 7.4 (95% CI) (4.9–8.0) (5.6–9.5) HR 1.32 (95% CI) (0.93–1.86) 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 13856
- exact text
- NCT00005636
- start
- 13845
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/54/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 54cf7e63-ef81-4ced-b833-a73ad8980230
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 20bda6357808aaafe1bcd8882382f9a130b4d009acdccbca54c39920e0a30764
- spl effective time
- 20251008
- spl set id
- 3ae68628-7ab0-4491-b3ae-6a8330b719c8
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b21b69871fcf8e5ea780
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 764ab64b-c642-4314-83a9-efee79fe83a3
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- caffcfc304d950e3b36abd73d207b0dd2003180853cedd498f47a1972495fa93
- payload
- application numbers
- NDA214657
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b21b69871fcf8e5ea780
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- CI) 1.32 (0.93-1.86) figure-1 Figure2 Figure3 Figure4 Figure5 Figure6 Figure7 Figure8 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 18576
- exact text
- NCT00005636
- start
- 18565
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/60/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 764ab64b-c642-4314-83a9-efee79fe83a3
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f14b6d5c8f017e0503c823927e08bef89aeae42994f80f7a2dfaadbc09020d18
- spl effective time
- 20251216
- spl set id
- 7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b323e4d79e93a87ad7ef
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- efadeccf-c754-46aa-999e-4da07a4cd2ce
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- fded84354ced6b048e49178e9ec923540d1276d9abe5c90de294f99376c51688
- payload
- application numbers
- NDA209472
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b323e4d79e93a87ad7ef
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- s) (95% CI) 6.2 (4.9,8.0) 7.4 (5.6,9.5) Hazard ratio (HR) a (95% CI) 1.32 (0.93,1.86) 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 19167
- exact text
- NCT00005636
- start
- 19156
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/98/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- efadeccf-c754-46aa-999e-4da07a4cd2ce
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fabb7322fa01234eab10e933fa6a8ff46ccdac2d8c21ba522dd36a9932c59267
- spl effective time
- 20260220
- spl set id
- 2308f4e8-21c8-49c1-a5b8-deb8610bac6a
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b73eeb110bde8052e1c3
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- b61d5060-31ca-4067-8e5c-d31e76c6390d
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- e2df662db97ab8b90fa36e27a20d6312c88d28bfb37408204b2353a974b87e68
- payload
- application numbers
- NDA214218
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b73eeb110bde8052e1c3
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- lue p<0.0001 Figure 7: Kaplan-Meier Curves for Overall Survival in PARAMOUNT Figure 7 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 10721
- exact text
- NCT00005636
- start
- 10710
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/17/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b61d5060-31ca-4067-8e5c-d31e76c6390d
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 087827990df0a5ff8c834c918e5c7224f184516e56a3af820814d5df35b0bab2
- spl effective time
- 20240724
- spl set id
- 3e087418-69ff-47fa-93c2-f28699309433
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b90d6025318fbb0af158
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- 21155bd2-118e-4ce6-adb8-dddc69ae34c7
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- c3832860cf8627d1efc6f76bf0b81ed81e538c89d614be5cb2bb53537bb29da0
- payload
- application numbers
- NDA208419
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b90d6025318fbb0af158
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- large cell carcinoma, or squamous cell carcinoma. Fig. 1 Fig. 2 Fig. 3 Fig. 4 1 1 1 1 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 19145
- exact text
- NCT00005636
- start
- 19134
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/16/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 21155bd2-118e-4ce6-adb8-dddc69ae34c7
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fff29cb5bde26b5953edee240ba643fc2fd422811dcfe7428495d3d09c04da80
- spl effective time
- 20221201
- spl set id
- 8b660f68-b770-4e0a-b2f9-25e663deecc3
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-e67426d0270c17e86fd4
- requested nct id
- NCT00005636
- primary nct id
- NCT00005636
- source kind
- fda_spl_label
- source record id
- b0e3847a-fdcf-405c-823c-180fa8dad9c2
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- e93c7a96e0a87929fdef2e8b2fc3a73d7a74a3092e0fc9b02b70f4bf1291c7aa
- payload
- application numbers
- NDA215179
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-e67426d0270c17e86fd4
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00005636
- occurrences
- context exact
- LC not specified as adenocarcinoma, large cell carcinoma, or squamous cell carcinoma. 14.2 Mesothelioma The efficacy of pemetrexed was evaluated in Study JMCH (NCT00005636), a multicenter, randomized (1:1), single-blind study conducted in patients with MPM who had received no prior chemotherapy. Patients were randomized (n=456) t
- end
- 18791
- exact text
- NCT00005636
- start
- 18780
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/6/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b0e3847a-fdcf-405c-823c-180fa8dad9c2
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c6b1ed4114fefd1c7f9a6371e475849253e8c11cc50aceaeb1a969a2604b8bb9
- spl effective time
- 20241128
- spl set id
- fe432994-e61b-4a87-8c98-cc20b847d0fe
Preserved source evidence · Not medical advice